Actively Recruiting
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Led by M.D. Anderson Cancer Center · Updated on 2025-11-06
508
Participants Needed
1
Research Sites
836 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
CONDITIONS
Official Title
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of acute myeloid leukemia, acute biphenotypic leukemia, high-risk myelodysplastic syndrome, or myeloid blast phase of chronic myeloid leukemia
- No prior potentially curative therapy for leukemia for frontline group; some prior therapies like hydroxyurea or low-dose cytarabine allowed
- For salvage group, previously treated, relapsed, or refractory AML, biphenotypic leukemia, or myeloid blast phase CML
- Age 18 to 65 years
- Adequate liver, kidney, and heart function as defined by specific laboratory and clinical measures
- Performance status of 2 or less on the ECOG scale
- Negative pregnancy test within 1 week for women of childbearing potential
- Ability to understand study requirements and provide signed informed consent
You will not qualify if you...
- Pregnancy or breastfeeding
- Uncontrolled illnesses including active infections, severe heart failure, unstable angina, significant arrhythmias, or psychiatric/social conditions limiting study compliance
- Known allergy to any chemotherapy components used in this study
- Men and women of childbearing potential who do not agree to use contraception before and during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
T
Tapan Kadia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here